GlassScriptPhysician profile
Michael Louis Dworkin
NPI 1922505924
$6,027.95
in general payments reported to CMS, 2019-2025
11 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $5,125 · 2023: $120 · 2024: $552 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mim Software INC. | $5,100.00 | 2022 | |
| Boston Scientific Corporation | $275.90 | 2023-2024 | Spaceoar Vue System - 10ml |
| Pfizer INC. | $141.42 | 2024-2025 | |
| Janssen Biotech, INC. | $130.81 | 2024-2025 | Erleada, Balversa, Akeega |
| Regeneron Healthcare Solutions, INC. | $101.84 | 2024-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $101.42 | 2024-2025 | Orgovyx |
| Novartis Pharmaceuticals Corporation | $55.24 | 2025 | |
| Coherus Oncology, INC. | $52.69 | 2024 | |
| Myriad Genetic Laboratories, INC. | $25.24 | 2024 | Prolaris |
| Abbvie INC. | $24.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.79 | 2023 | Tagrisso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Dworkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.